Bioresorbable Scaffolds (BRS): A Ten-Year Saga Turned Sour

Antonis S Manolis


The first generation bioresorbable scaffolds (BRS) did not deliver their promise for reduced risk of late stent thrombosis and neoatherosclerosis forming inside the stent and restoration of endothelial vasomotion. To our chagrin, the incidence of early, late and very late scaffold thrombosis was higher than conventional metallic stents leading to increased rates of adverse cardiovascular events and outcomes. Unfortunately, it took a decade to fully appreciate these major drawbacks. The manufacturer of the first, apparently hastily approved BRS in both Europe and the USA discontinued its production in September 2017. Nevertheless, hope remains and newer generation BRS are already in the pipeline expecting that improved technology and implantation strategies may overcome these severe limitations and finally recredit and reinstate the BRS concept. Rhythmos 2018;13(2): 26-29.


bioresorbable vascular scaffolds; coronary artery disease; acute coronary syndromes; coronary stents; scaffold thrombosis; stent thrombosis; adverse cardiovascular events

Full Text:



  • There are currently no refbacks.